Abstract
Previous studies with AS101 (ammonium trichloro[dioxyethylene-0, 0’]tellurate) have shown it to have significant immunostimulatory and tumoricidal effects with minimal toxicity. Nineteen consecutive patients with malignant mesothelioma were entered into protocol using AS101 at 3 mg/m2, I.V., three times a week. Males (13) predominated, the median age was 50 years (range 30–72). Seven patients were heavily pretreated. Median number of treatments was 10+ weeks (wks) with a range of 3–136 + wks. One patient had a CR (136 + wks), one had a PR (48 wks), and one a minimal response (39 + wks). All responding patients were previously treated with chemotherapy with no response and with progressive disease. Side effects included halitosis (14) and fever spikes (4). We conclude that AS101 is a promising agent in the treatment of mesothelioma and plan further studies in combination with chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
